Cel Sci (CVM) Interest Coverage Ratio (2010 - 2026)
Cel Sci (CVM) posted Interest Coverage Ratio of 0.7 for Q1 2026, up 97.86% sequentially from 32.63 in Q4 2025, and up 98.06% YoY from 0.35 in Q1 2025.
Cel Sci (CVM) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Cel Sci has reported Interest Coverage Ratio for 17 years, with the latest figure at 0.7 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 98.06% year-over-year to 0.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.91 (up 88.39% YoY) and the FY2025 annual result came in at 0.38, up 10.72% from the prior year.
- Interest Coverage Ratio grew to 0.7 in Q1 2026 per CVM's latest filing, from 32.63 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.47 in Q4 2023 and troughed at 155.01 in Q3 2024.
- A 5-year average of 18.14 and a median of 0.7 in 2026 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio jumped 99.87% in 2022, then plunged 6939.0% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 25.5 in 2022, then soared by 98.15% to 0.47 in 2023, then slumped by 6939.0% to 33.18 in 2024, then grew by 1.68% to 32.63 in 2025, then soared by 97.86% to 0.7 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.7, 32.63, and 3.19 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 1.42 |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.70 |
| Dec 31, 2025 | -32.63 |
| Sep 30, 2025 | -3.19 |
| Jun 30, 2025 | -0.56 |
| Mar 31, 2025 | -35.92 |
| Dec 31, 2024 | -33.18 |
| Sep 30, 2024 | -155.01 |
| Jun 30, 2024 | -0.54 |
| Mar 31, 2024 | -0.54 |
| Dec 31, 2023 | -0.47 |
| Sep 30, 2023 | -12.16 |
| Jun 30, 2023 | -0.54 |
| Mar 31, 2023 | -0.52 |
| Dec 31, 2022 | -25.50 |
| Sep 30, 2022 | -5.86 |
| Jun 30, 2022 | -0.49 |
| Mar 31, 2022 | -0.52 |
| Dec 31, 2021 | -30.47 |
| Sep 30, 2021 | -68.34 |
| Jun 30, 2021 | -373.45 |